CuraTeQ Reports P-III Trial Data on BP11 (Biosimilar, Xolair) in Chronic Spontaneous Urticaria

Why It Matters

Equivalence confirms BP11 can enter the lucrative CSU market, offering a lower‑cost alternative to Xolair and potentially reshaping payer dynamics. The data also pave the way for faster regulatory approval, accelerating patient access to affordable therapy.

Key Takeaways

• BP11 matched Xolair efficacy in chronic spontaneous urticaria
• 608 patients across ~80 sites showed equivalence at 12 weeks
• Predefined margins confirmed biosimilarity for ISS7 score changes
• EMA and FDA filings planned by Q2 2026
• Biosimilar could lower treatment costs for CSU patients

Pulse Analysis

Xolair (omalizumab) has become the cornerstone biologic for chronic spontaneous urticaria (CSU) after demonstrating rapid symptom control in patients unresponsive to antihistamines. Despite its clinical success, the drug’s price—often exceeding $30,000 per year in the United States—has limited broader adoption, especially in health‑system‑driven markets. Biosimilars promise to introduce price competition while preserving therapeutic efficacy, a trend already reshaping oncology and rheumatology. CuraTeQ Biologics, a relatively new entrant focused on affordable biologics, aims to capture a share of the growing CSU market by offering a lower‑cost alternative.

The phase‑III, double‑blind trial enrolled 608 CSU patients across roughly 80 global sites, comparing the biosimilar BP11 with reference Xolair at the standard 300 mg dose. The primary endpoint—change in the Itch Severity Score (ISS7) at week 12—met predefined equivalence margins, confirming that BP11 delivers comparable itch reduction and safety profile. Such robust data satisfy stringent regulatory expectations for biosimilarity, streamlining the pathway to approval in both the European Medicines Agency and the U.S. Food and Drug Administration. CuraTeQ plans to submit dossiers by the end of Q2 2026.

Assuming approval, BP11 could shave several thousand dollars off the annual treatment cost, expanding access for patients and easing payer budgets. The entry of a biosimilar also pressures the originator to consider price adjustments or value‑added services, potentially reshaping the CSU therapeutic landscape. Moreover, successful commercialization would reinforce CuraTeQ’s pipeline credibility, supporting future biosimilar launches in allergy and immunology. Investors will watch the regulatory milestones closely, as the timing and pricing strategy will dictate market penetration and revenue forecasts for the next decade.